Age‐restricted functional and developmental differences of neonatal platelets

Abstract

BackgroundDevelopmental ontogeny of neonatal thrombopoiesis retains characteristics that are distinct from adults although molecular mechanisms remain unestablished. MethodsWe applied multiparameter quantitative platelet responses with integrated ribosome profiling/transcriptomic studies to better define gene/pathway perturbations regulating the neonatal‐to‐adult transition. A bioinformatics pipeline was developed to identify stable, neonatal‐restricted platelet biomarkers for clinical application. ResultsCord blood (CB) platelets retained the capacity for linear agonist–receptor coupling linked to phosphatidylserine (PS) exposure and α‐granule release, although a restricted block in cross‐agonist activation pathways was evident. Functional immaturity of synergistic signaling pathways was due to younger ontogenetic age and singular underdevelopment of the protein secretory gene network, with reciprocal expansion of developmental pathways (E2F, G2M checkpoint, c‐Myc) important for megakaryocytopoiesis. Genetic perturbations regulating vesicle transport and fusion (TOM1L1, VAMP3, SNAP23, and DNM1L) and PS exposure and procoagulant activity (CLCN3) were the most significant, providing a molecular explanation for globally attenuated responses. Integrated transcriptomic and ribosomal footprints identified highly abundant (ribosome‐protected) DEFA3 (encoding human defensin neutrophil peptide 3) and HBG1 as stable biomarkers of neonatal thrombopoiesis. Studies comparing CB‐ or adult‐derived megakaryocytopoiesis confirmed inducible and abundant DEFA3 antigenic expression in CB megakaryocytes, ~3.5‐fold greater than in leukocytes (the most abundant source in humans). An initial feasibility cohort of at‐risk pregnancies manifested by maternal/fetal hemorrhage (chimerism) were applied for detection and validation of platelet HBG1 and DEFA3 as neonatal thrombopoiesis markers, most consistent for HBG1, which displayed gestational age‐dependent expression. ConclusionsThese studies establish an ontogenetically divergent stage of neonatal thrombopoiesis, and provide initial feasibility studies to track disordered fetal‐to‐adult megakaryocytopoiesis in vivo.